CompletedNot applicableNCT01626092
Reduced-Intensity Hematopoietic Stem Cell Transplant for High Risk Lysosomal and Peroxisomal Disorders
Studying Alpha-mannosidosis, infantile form
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Masonic Cancer Center, University of Minnesota
- Principal Investigator
- Weston Miller, MDMasonic Cancer Center, University of Minnesota
- Intervention
- Campath-1H(drug)
- Enrollment
- 3 enrolled
- Eligibility
- 55 years · All sexes
- Timeline
- 2012 – 2013
Study locations (1)
- Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01626092 on ClinicalTrials.gov